Adaptimmune

The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Readouts And IPOs
The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Readouts And IPOs
Yahoo/Benzinga
Regeneron
Sanofi
Praluent
FDA
Heron Therapeutics
HTX-011
Nabiva
Orchard Therapeutics
Akari Therapeutics
Aldeyra Therapeutics
BioTime
Audentes Therapeutics
Adaptimmune
GW Pharma
Ionis
Biogen
Ovid Therapeutics
TransMedics
IPOs
Trevi Therapeutics
Flag link:
Adaptimmune reports zero responses across three T cell therapy trials
Adaptimmune reports zero responses across three T cell therapy trials
BioCentury
Adaptimmune
t-cell therapies
clinical trials
Flag link:
Dose Escalation Cohort to be Initiated in Adaptimmune's MAGE-A4 SPEAR T-Cell Basket Study
Dose Escalation Cohort to be Initiated in Adaptimmune's MAGE-A4 SPEAR T-Cell Basket Study
CP Wire
Adaptimmune
MAGE-A4
solid tumors
Flag link:
Dose Escalation Cohort to be Initiated in Adaptimmune's MAGE-A4 SPEAR T-Cell Basket Study
Adaptimmune
MAGE-A4
Flag link:
Adaptimmune Completes Transition of Pioneering T-Cell Therapy to GSK – Will Receive $27 Million Payment
Adaptimmune Completes Transition of Pioneering T-Cell Therapy to GSK – Will Receive $27 Million Payment
CP Wire
Adaptimmune
GSK
GSK3377794
T-cells
Flag link:
Adaptimmune Completes Transition of Pioneering T-Cell Therapy to GSK – Will Receive $27 Million Payment
Adaptimmune
GSK
GSK3377794
Flag link:
Ramping back up on oncology, GSK takes an option on Adaptimmune’s TCR cancer drug
Ramping back up on oncology, GSK takes an option on Adaptimmune’s TCR cancer drug
Endpoints
GSK
oncology
Adaptimmune
TCR therapeutics
Flag link:
After setback, Adaptimmune revamps T cell study
After setback, Adaptimmune revamps T cell study
BioPharma Dive
Adaptimmune
t cell therapy
NY-ESO SPEAR
ovarian cancer
Flag link:
Adaptimmune gets a partial hold on pivotal T-cell study, but it seems OK to breathe now
Adaptimmune gets a partial hold on pivotal T-cell study, but it seems OK to breathe now
Endpoints
Adaptimmune
T-cells
myxoid round cell liposarcoma
CAR-T
cancer immunotherapy
Flag link:
These 5 Biotech Stocks Under $10 Are About to Break Out
These 5 Biotech Stocks Under $10 Are About to Break Out
TheStreet.com
biotech
Ardelyx
Biocryst
Affimed
Adaptimmune
Sangamo BioSciences
Flag link:
Adaptimmune and GSK Expand Strategic Immunotherapy Collaboration
Adaptimmune and GSK Expand Strategic Immunotherapy Collaboration
Yahoo
Adaptimmune
GSK
immunotherapy
Flag link:
9 Biotech Picks for 2016
9 Biotech Picks for 2016
Barron's
biotech
Adaptimmune
Dermira
FibroGen
Incyte
Intra-Cellular Therapies
Seres Therapeutics
Ophthotech
Neurocrine Biosciences
Paratek
Flag link:
Adaptimmune pockets GSK payouts after tripling size of TCR trial
Adaptimmune pockets GSK payouts after tripling size of TCR trial
Fierce Biotech
Adaptimmune
GSK
synovial sarcoma
NY-ESO-1
Flag link:
3 Biotech Stocks Wall Street Hates
3 Biotech Stocks Wall Street Hates
Motley Fool
Northwest Biotherapeutics
Adaptimmune
MannKind
Flag link:
Drug developer Adaptimmune skids after IPO raises $191M
Drug developer Adaptimmune skids after IPO raises $191M
Yahoo/AP
Adaptimmune
IPOs
Flag link:
Another IPO Filed In Hot Cancer Immunotherapy Field
Another IPO Filed In Hot Cancer Immunotherapy Field
Investors.com
IPOs
cancer immunotherapy
Adaptimmune
Flag link:
Adaptimmune's novel cancer treatment posts promising early results
Adaptimmune's novel cancer treatment posts promising early results
Fierce Biotech
Adaptimmune
GSK
cancer immunotherapy
Flag link:
Adaptimmune raises $104 mln to develop immune-system cancer drugs
Adaptimmune raises $104 mln to develop immune-system cancer drugs
Yahoo/Reuters
Adaptimmune
immuno-oncology
Flag link:
GSK in $350 million deal to develop cancer drugs with UK biotech firm
GSK in $350 million deal to develop cancer drugs with UK biotech firm
Yahoo/Reuters
GSK
R&D
cancer
UK
Adaptimmune
Flag link: